Explore more publications!

Guinea Bissau Health Bulletin: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Guinea Bissau Health Bulletin.

Press releases published on October 20, 2025

BPGbio and Icahn School of Medicine at Mount Sinai Publish Landmark Study on the Living Human Brain, Unlocking New Molecular Insights Into Neurodegenerative Disease
BioCryst to Report Third Quarter 2025 Financial Results on November 3
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones
WeightWatchers Collaborates With Amazon Pharmacy to Increase Medication Delivery Speed, Convenience and Savings For Members
Kratom Products for Energy and Balance: Kratom Bird Expands Its Collection in 2025
Biodesix to Report Third Quarter 2025 Financial Results on November 3, 2025
RadNet, Inc. Announces Date of its Third Quarter 2025 Financial Results Conference Call
The Ensign Group Schedules Third Quarter Earnings Call for Tuesday, November 4, 2025
Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares
Aicuris Presents Positive Phase 2 Results for Pritelivir and Favorable Phase 1 Safety Data for AIC468 at ID Week 2025
Angelini Ventures Deepens Commitment to CoMind, a Neurotech Redefining Brain Monitoring, with Participation in $60 Million Round Bringing Total Funding to $102.5 Million
Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy
ImmunOs Therapeutics Reports Promising Clinical Activity of IOS-1002 in Advanced Solid Tumors
Medela AG Introduces the New Motion InBra™ Wearable Breast Pump – Where Dependable Performance Meets Everyday Comfort
Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
Communiqué de presse : ESMO : les données de l’essai de phase 2 soulignent le potentiel thérapeutique prometteur d’AlphaMedix™ en tant que pionnier de la nouvelle classe des alphathérapies ciblées contre les tumeurs neuroendocrines (...)
IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025
Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio
Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions